Brean Capital Maintains Buy On MEI Pharma Shares, $16 PT
Brean Capital analyst Jonathan Aschoff maintained a Buy rating on MEI Pharma (NASDAQ:MEIP) with a $16 price target, which represents a potential upside of 101% from where the stock is currently trading.
Aschoff commented, “Nearer term we look forward to additional Phase 2 results with pracinostat plus azacitidine for front-line elderly AML at ASH, and we view data from the recent abstract as impressive, with 8 of 14 evaluable patients (57%) achieving CR/CRi mostly after 1 or 2 cycles, whereas 3 of 9 evaluable patients (33%) had a CR/CRi as of last ASCO.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.6% and a 63.5% success rate. Aschoff has a 13.9% average return when recommending MEIP, and is ranked #152 out of 3367 analysts.